Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964259 · ClinicalTrials.gov registry record · Phase 1
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03964259 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 10 participants.
The verdict
NCT03964259, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
To determine whether a reduced volume hydration regimen will lead to a shorter time to methotrexate clearance when compared to a standard intravenous (IV) hydration regimen.
Interventions
- DRUG Intravenous fluids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-10-02 |
| Est. Completion | 2022-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03964259
The ClinicalTrials.gov registry entry for NCT03964259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous fluids is the first listed.
NCT03964259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03964259 about?
NCT03964259 is a clinical study titled "Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia". To determine whether a reduced volume hydration regimen will lead to a shorter time to methotrexate clearance when compared to a standard intravenous (IV) hydration regimen.
What is the current status of trial NCT03964259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-10-02. Estimated completion is 2022-12-28.
What interventions are being tested in trial NCT03964259?
The interventions under investigation include: Intravenous fluids (DRUG).
Who is sponsoring clinical trial NCT03964259?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.